1. Home
  2. QLGN vs DBGI Comparison

QLGN vs DBGI Comparison

Compare QLGN & DBGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • QLGN
  • DBGI
  • Stock Information
  • Founded
  • QLGN 1996
  • DBGI 2012
  • Country
  • QLGN United States
  • DBGI United States
  • Employees
  • QLGN N/A
  • DBGI N/A
  • Industry
  • QLGN Biotechnology: Pharmaceutical Preparations
  • DBGI Clothing/Shoe/Accessory Stores
  • Sector
  • QLGN Health Care
  • DBGI Consumer Discretionary
  • Exchange
  • QLGN Nasdaq
  • DBGI Nasdaq
  • Market Cap
  • QLGN 2.5M
  • DBGI 2.2M
  • IPO Year
  • QLGN N/A
  • DBGI 2021
  • Fundamental
  • Price
  • QLGN $0.16
  • DBGI $0.93
  • Analyst Decision
  • QLGN
  • DBGI
  • Analyst Count
  • QLGN 0
  • DBGI 0
  • Target Price
  • QLGN N/A
  • DBGI N/A
  • AVG Volume (30 Days)
  • QLGN 337.7K
  • DBGI 141.9K
  • Earning Date
  • QLGN 08-14-2024
  • DBGI 08-19-2024
  • Dividend Yield
  • QLGN N/A
  • DBGI N/A
  • EPS Growth
  • QLGN N/A
  • DBGI N/A
  • EPS
  • QLGN N/A
  • DBGI N/A
  • Revenue
  • QLGN N/A
  • DBGI $13,019,275.00
  • Revenue This Year
  • QLGN N/A
  • DBGI N/A
  • Revenue Next Year
  • QLGN N/A
  • DBGI N/A
  • P/E Ratio
  • QLGN N/A
  • DBGI N/A
  • Revenue Growth
  • QLGN N/A
  • DBGI N/A
  • 52 Week Low
  • QLGN $0.14
  • DBGI $0.64
  • 52 Week High
  • QLGN $1.10
  • DBGI $12.80
  • Technical
  • Relative Strength Index (RSI)
  • QLGN 32.97
  • DBGI 45.32
  • Support Level
  • QLGN $0.14
  • DBGI $0.79
  • Resistance Level
  • QLGN $0.22
  • DBGI $0.89
  • Average True Range (ATR)
  • QLGN 0.02
  • DBGI 0.11
  • MACD
  • QLGN -0.00
  • DBGI 0.02
  • Stochastic Oscillator
  • QLGN 21.12
  • DBGI 59.71

About QLGN Qualigen Therapeutics Inc.

Qualigen Therapeutics Inc is a early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells.

About DBGI Digital Brands Group Inc.

Digital Brands Group Inc offers a variety of apparel through numerous brands on a both direct-to-consumer and wholesale basis. It has expanded into an omnichannel brand offering the styles and content not only online but at selected wholesale and retail storefronts. Its brand portfolio consists of Bailey 44, DSTLD, Harper & Jones, Stateside, and Sundry.

Share on Social Networks: